The predictive value of CD8, CD4, CD68 and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase

Cancer

Volumn 104, Issue 6, 2005, Pages 1246-1254

  Piras, Franca ^a   Colombari, Romano ^b   Minerba, Luigi ^c   Murtas, Daniela ^a   Floris, Carlo ^d   Maxia, Cristina ^a   Corby, Arianna ^a,e   Perra, M Teresa ^a   Sirigu, Paola ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b City Hospital   (Italy)

^c Territorial Department of Nephrology and Dialysis   (Italy)

^d Ospedale Oncologico A Businco   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

CD4; CD68; CD8; Human leukocyte antigen D related; Prognosis

Indexed keywords

CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; LEUKOCYTE ANTIGEN; MELAN A; MELANOMA ANTIGEN 1; PROTEIN S 100;

ADOLESCENT; ADULT; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CELL DENSITY; CHILD; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNE SYSTEM; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN CARCINOMA; T LYMPHOCYTE SUBPOPULATION; TISSUE DISTRIBUTION; TUMOR LOCALIZATION;

EID: 24644488201     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21283     Document Type: Article

References (34)

1. Clark WH Jr., Elder DE, Guerry DP IV, et al. Model predicting survival in Stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893-1904.
2. Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002;138:603-608.
3. Ostmeier H, Fuchs B, Otto F, et al. Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol. 2001;145:203-209.
4. Marghoob AA, Koenig K, Bittencourt FV, Kopf AW, Bart RS. Below thickness and Clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer staging. Cancer. 2000;88:589-595.
5. Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR 3rd. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol. 2001;137: 1169-1173.
6. Carlson JA, Dickersin GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer. 1995;75:478-494.
7. Ribatti D, Ennas MG, Vacca A, et al. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest. 2003;33:420-425.
8. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
9. Balch CM. Cutaneous melanoma. In: Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual, 6th ed. New York: Springer Verlag, 2002:209-217.
10. Carlson JA, Slominski A, Linette GP, et al. Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging. Am J Clin Pathol. 2003;120(Suppl):101-127.
11. Cook MG. The significance of inflammation and regression in melanoma. Virchows Arch A Pathol Anat Histopathol. 1992;420:113-115.
12. Busam KJ, Antonescu CR, Marghoob AA. Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. Am J Clin Pathol. 2001;115:856-860.
13. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-1310.
14. Mihm MC Jr., Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996;74:43-47.
15. Tuthill RJ, Unger JM, Liu PY, Flaherty LE, Sondak VK. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol. 2002;4:504-511.
16. Hakansson A, Gustafsson B, Krysander L, Hakansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to Interferon alpha treatment. Br J Cancer. 1996;74:670-676.
17. Hakansson A, Gustafsson B, Krysander L, Hakansson L. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res. 1998;18:33-39.
18. Hakansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Hakansson L. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br J Cancer. 2001;85:1871-1877.
19. Håkansson A, Håkansson L, Gustafsson B. On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation. Melanoma Res. 2003;13: 401-407.
20. Qiang L, Yi J, Fu-De C. Melanoma vaccine based on the vector of membrane fusogenic liposomes. Pharmazie. 2004; 59:263-267.
21. Obata C, Zhang M, Moroi Y, et al. Formalin-fixed tumor cells effectively induce antitumor immunity both in prophylactic and therapeutic conditions. J Dermatol Sci. 2004;34:209-219.
22. Dissanayake SK, Thompson JA, Bosch JJ, et al. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex Class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res. 2004;64:1867-1874.
23. Konstadoulakis MM, Vezeridis M, Hatziyianni E, et al. Molecular oncogene markers and their significance in cutaneous malignant melanoma. Ann Surg Oncol. 1998;5:253-260.
24. Zehntner S, Townsend W, Parkes J, et al. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology. 1999;31:116-122.
25. Torisu-Itakura H, Furue M, Kuwano M, Ono M. Co-expression of thymidine phosphorylase and heme oxygenase-1 in macrophages in human malignant vertical growth melanomas. Jpn J Cancer Res. 2000;91:906-910.
26. Bodey B, Bodey B Jr., Siegel SE, Kaiser HE. Controversies on the prognostic significance of tumor infiltrating leukocytes in solid human tumors. Anticancer Res. 2000;20:1759-1768.
27. Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology, 3rd ed. Philadelphia: WB Saunders Company, 1997.
28. Bernsen MR, Diepstra JH, van Mil P, et al. Presence and localization of T-cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells. J Pathol 2004;202:70-79.
29. Riley PA. Melanoma and the problem of malignancy. Tohoku J Exp Med. 2004;204:1-9.
30. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159:237-243.
31. Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol. 2003;200:255-268.
32. Salio M, Cella M, Vermi W, et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol. 2003;33:1052-1062.
33. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42:1414-1421.
34. Ladanyi A. Function and prognostic significance of immune cells infiltrating human tumors. Magy Onkol. 2004;48:49-56.